ArticleJournal of blood medicine2026
Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study.
Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate treatment and disease burden among patients with polycythemia vera (PV) receiving the current standard of care (SoC) in the US. Patients and Methods: This retrospective study utilized MarketScan® Commercial/Medicare Databases to identify patients with PV diagnosis and treatment claims between 1/1/2011-12/31/2022 (index date=earliest PV treatment date), continuous enrollment (6 months pre-index and ≥12 months post-index), and no pre-index disease progression (myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome). Patients were categorized by thrombosis risk (high/low-risk) and 12-month post-index treatments: phlebotomy (PHL) only, hydroxyurea (HU) only, PHL+HU, or ruxolitinib/interferons (RUX/IFN). Outcomes included incident TE, iron deficiency anemia, disease progression, and PV-related symptoms. Hematocrit (HCT) control was evaluated in patients with ≥2 HCTs post-index (HCT analysis). All-cause costs during the 12 months post-TE were reported in patients with an incident TE and ≥12 months post-TE follow-up (TE analysis). Results: Among 11,311 patients (51.8% high-risk; 48.2% low-risk; median follow-up ~2.8 years), 12-month post-index treatments included PHL only (75.0%), HU only (12.2%), PHL+HU (10.9%), and RUX/IFN (1.9%). Frequent PHL (≥3 PHL in 6 months or ≥5 PHL in 12 months post-index; 46.2% of PHL users) and high-dose HU (≥1000mg/day; 41.7% of HU users) were common. Within 12 months post-index, 50.9% of patients experienced burdensome treatment (frequent PHL, high-dose HU) and/or an incident TE. During the full follow-up, 15.3% experienced incident TE, 9.6% experienced incident iron deficiency anemia, 4.4% experienced disease progression, and 83.2% experienced symptoms. For the HCT analysis (N=1,268), 85.3% had uncontrolled HCTs≥45%, with 55.4% having HCTs≥50%. For the TE analysis (N=1,159), mean 12-month all-cause costs post-TE were $71,195, with 29.2% attributable to the index TE. Conclusion: Patients with PV have high treatment and disease burden with the current SoC. Current PV therapies (PHL, cytoreductive agents) do not consistently maintain HCT<45%, leaving patients at increased risk for life-threatening and costly TEs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.